GPR110 inhibitors belong to a specialized category of chemical compounds that have garnered attention in the field of molecular pharmacology and drug discovery. GPR110, also known as ADGRF1, is a G-protein coupled receptor (GPCR) belonging to the adhesion GPCR subfamily. This receptor is widely distributed in various tissues and plays a crucial role in cellular signaling and regulation. GPR110 is characterized by its distinctive structure, comprising a long extracellular N-terminus, a transmembrane region, and an intracellular C-terminus. It is associated with various intracellular signaling pathways and is implicated in processes such as cell adhesion, migration, and tissue development. GPR110 inhibitors, as their name suggests, are chemical compounds designed to interact with GPR110 and modulate its activity, providing valuable tools for elucidating the biological functions and signaling pathways associated with this receptor.
The mechanism of action of GPR110 inhibitors often involves their binding to the GPR110 receptor, either at its extracellular N-terminus or within its transmembrane domain. By doing so, these inhibitors can alter the receptor's conformation and interfere with its ability to activate downstream signaling pathways, effectively attenuating the cellular responses mediated by GPR110 activation. This modulation of GPR110 activity can have implications in diverse cellular processes, ranging from cell adhesion and migration to tissue development and homeostasis. Therefore, the study of GPR110 inhibitors holds significance in advancing our understanding of the role of GPR110 in various biological contexts and contributes to the broader field of GPCR research.